Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Validation of the Greek Version of the Ureteral Stent Symptom Questionnaire (USSQ): A prospective clinical Study.

Urologia·2026

Same author

Impact of prior shock wave lithotripsy on outcomes of retrograde intrarenal surgery for 1-2 cm lower pole kidney stones: a comparative analysis by the EAU-YAU Endourology & Urolithiasis Working Group.

Central European journal of urology·2026

Same author

Small procedures, big complications.

World journal of urology·2026

Same author

Novel devices for intrarenal pressure monitoring: are they the future?

Current opinion in urology·2026

Same author

Real-Time Assessment of Surgical Margins During Radical Prostatectomy: A Comprehensive Review.

Archivos espanoles de urologia·2026

Same author

Health status assessment and surgical decision-making for older adults in urology: Results from an International Survey of the EAU Young Academic Urology Group.

The French journal of urology·2026

Search research articles

Related Experiment Video

Updated: Oct 6, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate cancer immunotherapy.

Iraklis Mitsogiannis¹, Lazaros Tzelves¹, Athanasios Dellis^1,2

¹2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Expert Opinion on Biological Therapy

|January 17, 2022

Summary

This summary is machine-generated.

Prostate cancer immunotherapy research is advancing, with sipuleucel-T approved. Further trials are needed to determine optimal patient selection and disease stages for emerging treatments like ipilimumab and olaparib.

Keywords:

Immunotherapy PARP inhibitors PD-1/PD-L1 inhibitors PSMA prostate cancer vaccines

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Experiment Videos

Last Updated: Oct 6, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Area of Science:

Oncology
Immunology
Medical Research

Background:

Prostate cancer (PC) treatments historically target hormonal pathways.
Advances in understanding molecular pathways have paved the way for immunotherapies.
Modifying immunological mechanisms offers new therapeutic avenues for PC.

Purpose of the Study:

To review completed and ongoing research on prostate cancer immunotherapy.
To identify eligible Phase III trials for various immunotherapies against PC.

Main Methods:

Conducted a literature search across major databases (PubMed/MEDLINE, Scopus, Cochrane) and clinicaltrials.gov.
Included studies on vaccine therapies, CTLA-4 inhibitors, PD-1/PD-L1 inhibitors, PARP inhibitors, PSMA-targeted therapies, and tyrosine kinase inhibitors.
Focused on completed or ongoing Phase III trials up to 07/2021.

Main Results:

Sipuleucel-T is the only FDA-approved immunotherapy for prostate cancer.
Ipilimumab and olaparib have demonstrated significant overall survival benefits compared to placebo.
Ongoing research aims to identify specific patient populations and disease stages that benefit most from these therapies.

Conclusions:

Prostate cancer immunotherapy faces challenges due to tumor heterogeneity and complex immune microenvironments.
Further clinical trials are crucial to define the optimal use of emerging immunotherapies.
PSMA-targeted treatments represent a promising area of current evaluation.